Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Abicipar pegol (Primary) ; Ranibizumab
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms REACH
- Sponsors Allergan
- 30 Jul 2014 Status changed from active, no longer recruiting to completed according to the ClinicalTrials.gov record.
- 01 Jul 2014 Results published in the Molecular Partners AG Media Release.
- 17 Dec 2013 New trial record